BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

This article was originally published here

The Phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805. ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed

The post BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply